Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ICU Medical's Enterprise Value is €4,809 Mil.
ICU Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €71 Mil. Therefore, ICU Medical's EV-to-EBIT ratio for today is 67.29.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ICU Medical's Enterprise Value is €4,809 Mil.
ICU Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €244 Mil. Therefore, ICU Medical's EV-to-EBITDA ratio for today is 19.67.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ICU Medical's Enterprise Value is €4,809 Mil.
ICU Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €1,857 Mil. Therefore, ICU Medical's EV-to-Revenue ratio for today is 2.59.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, ICU Medical's Enterprise Value is €4,809 Mil.
ICU Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €125 Mil. Therefore, ICU Medical's EV-to-FCF ratio for today is 38.54.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
ICU Medical (STU:IC7) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ICU Medical's current Enterprise Value is €4,809 Mil.
ICU Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €71 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ICU Medical's current Enterprise Value is €4,809 Mil.
ICU Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €244 Mil.
ICU Medical's current Enterprise Value is €4,809 Mil.
ICU Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,857 Mil.
ICU Medical's current Enterprise Value is €4,809 Mil.
ICU Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €203 Mil.
ICU Medical's current Enterprise Value is €4,809 Mil.
ICU Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €125 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical Enterprise Value Related Terms
ICU Medical Enterprise Value Historical Data
* Premium members only.
The historical data trend for ICU Medical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ICU Medical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ICU Medical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (STU:IC7) has a Enterprise Value of €4,809 Mil as of Aug. 17, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ICU Medical and its competitors.
Is ICU Medical's Enterprise Value too high?
ICU Medical's current Enterprise Value is €4,809 Mil. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Enterprise Value compare to NVST and MMSI?
ICU Medical's Enterprise Value of €4,809 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ICU Medical and its competitors. ICU Medical's current Enterprise Value is €4,809 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Enterprise Value is €4,809 Mil. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Enterprise Value is €4,809 Mil as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
Enterprise Value: €4,809 Mil
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
